Tirofiban Hydrochloride Injection, Solution
Product Images NDC 68083-145

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Tirofiban Hydrochloride (NDC 68083-145). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Gland Pharma Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Tirofiban-spl-bag (Tirofiban Spl Bag)

Label for Tirofiban Hydrochloride Injection 12.5 mg per 250 mL intravenous solution by Gland Pharma Limited. The single-dose, sterile, nonpyrogenic, iso-osmotic premixed bag features directions, storage conditions, ingredient details, and a barcode. The label includes space for the lot number and expiration date.*

FDA Label Image

Tirofiban-spl-carton (Tirofiban Spl Carton)

Label for Tirofiban Hydrochloride Injection 12.5 mg per 250 mL (50 mcg per mL) intravenous solution. The label includes storage instructions, cautions, and manufacturer information for Gland Pharma Limited, Hyderabad, India. It features the NDC 68083-145-01 and details about the single-dose, sterile, iso-osmotic container.*

FDA Label Image

Tirofiban-spl-container (Tirofiban Spl Container)

Label for Tirofiban Hydrochloride Injection 12.5 mg per 250 mL intravenous solution by Gland Pharma Limited. The label indicates it is a single-dose, sterile, iso-osmotic product requiring storage protection from light. The label includes the NDC 68083-145-01, manufacturing and storage details, and a barcode.*

FDA Label Image

Tirofiban-spl-fig-1 (Tirofiban Spl Fig 1)

A formula calculation from a dosing instruction panel showing how to determine the bolus volume in milliliters based on patient body weight in kilograms, using a fixed concentration of 50 mcg/mL and a dosing rate of 25 mcg/kg.*

FDA Label Image

Tirofiban-spl-fig-2 (Tirofiban Spl Fig 2)

A formula showing the infusion rate calculation for Tirofiban hydrochloride injection for patients with creatinine clearance above 60 mL/min. The formula includes dosage in micrograms per kilogram per minute multiplied by body weight and a time conversion factor, divided by concentration in micrograms per milliliter.*

FDA Label Image

Tirofiban-spl-fig-3 (Tirofiban Spl Fig 3)

A mathematical formula showing the calculation of infusion rate for a drug infusion when creatinine clearance (CrCl) is greater than 60 mL/min. The equation calculates infusion rate in mL per hour based on dosage in mcg/kg/min, patient weight in kg, and drug concentration in mcg/mL, resulting in a sample value of 10.8 mL/h.*

FDA Label Image

Tirofiban-spl-fig-4.jpg (Tirofiban Spl Fig 4)

A formula panel illustrating the infusion rate calculation for Tirofiban hydrochloride injection for patients with creatinine clearance of 60 mL/min or less. The formula uses patient weight, time, and concentration to determine the rate in mL/hour.*

FDA Label Image

Tirofiban-spl-fig-3 (Tirofiban Spl Fig 5)

A line graph titled "Composite Endpoint 180-day Follow-up" comparing the proportion with endpoint over study days between two groups: Heparin alone and Tirofiban Hydrochloride Injection plus Heparin. The graph indicates a 22% risk reduction early in the study and a 19% risk reduction by day 180 favoring the combination therapy, with corresponding p-values of 0.029 and 0.024, respectively.*

FDA Label Image

Tirofiban-spl-structure (Tirofiban Spl Structure)

Chemical structure diagram of Tirofiban hydrochloride, showing molecular bonds and connected functional groups including aromatic rings and sulfonamide moieties.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.